OPHLF - Ono Pharmaceutical Co. Ltd. (OPHLF) Q1 2024 Earnings Call Transcript
2024-05-11 21:00:08 ET
Ono Pharmaceutical Co., Ltd. (OPHLF)
Q1 2024 Earnings Conference Call
May 09, 2024, 08:30 PM ET
Company Participants
Gyo Sagara - Representative, Director, Chairman of the Board and CEO
Tatsuya Okamoto - Corporate Officer, Executive Director of Clinical Development
Satoshi Takahaki - Corporate Executive Officer, Sales and Marketing
Conference Call Participants
Fumiyoshi Sakai - UBS
Kazuaki Hashiguchi - Daiwa
Hidemaru Yamaguchi - Citi
Takashi Akahane - Tokai, Tokyo
Presentation
Unidentified Company Representative
Thank you very much for your participating on FY 2023 Financial Results Meeting. And if everyone has come. We'd like to start this meeting. And today we have the meeting in a hybrid manner. So we have the participants here in the venue and also online. And let me introduce you today's participant.
Representative, Director, Chairman of the Board and CEO, Sagara; and Representative, Director, Corporate Officer, Executive Director, Clinical Development Takino; and Takahaki, the Corporate Executive Officer, Sales and Marketing; and Okamoto, Corporate Officer, Executive Director of Clinical Development, and Itoh from the Corporate Strategy Management and Tanigawa. And I'm [indiscernible] from the IR Corporate Communication Imola. And let me introduce you today's agenda.
The first award would have the financial announcement for FY '23 and forecast of 2024 by Mr. Sagara. And also the status of the cross shareholdings will be explained by Mr. Sagara and Okamoto - Mr. Okamoto will explain you development of pipeline product basis, and Mr. Takahagi will explain to you the trend of upheaval.
And as you know, the materials we use for today's meeting, is already available on our homepage. So please refer to it. And without ado, I'd like to invite Mr. Sagara to the podium to explain you the financial announcement for FY 2023.
Gyo Sagara
Good morning, everyone. I got a cold, and I'm sorry for this voice. It's just a cold, so please bear with me for speaking in this voice. So let me start. And this is another busy slide. The venue was ¥502.7 billion, so the first time we exceeded ¥500 billion. And both the profit and product sales and royalties in others increased....
Ono Pharmaceutical Co., Ltd. (OPHLF) Q1 2024 Earnings Call Transcript